leisure time -WSS

leisure time

author：fashion 2025-10-02 00:42:12 - browse：61

Photography of the US department of health and human services in Silver Spring MD — Manuel Balce Ceneta/AP

An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

Triple-check your data or we’ll reject your device, the FDA warned.

The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Chris Christie meets with Zelenskyy during Ukraine trip

WSS

New CMS data security rules will hurt Medicare, Medicaid research

Surprise medical billing ban raises prices elsewhere

Pharma showers House GOP doctor with campaign cash

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Chris Christie meets with Zelenskyy during Ukraine trip

Medicare slashes safety net hospital payments by nearly $1 billion

hotspot

leisure time

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Late stage cancers on the rise after pandemic delayed screenings

How to save PrEP access — and even expand it

Weight loss drugs aren’t covered by Obamacare. That may change

Peter Hotez and the public health issue of online harassment

Florida officials tell state schools to teach AP Psychology 'in its entirety'

At least 13 dead in Texas as scorching temps continue

Late stage cancers on the rise after pandemic delayed screenings

United colonoscopy coverage change 'may cost lives,' doctors say

Group behind ProMed defends move to subscription

knowledge

CDC recommends RSV monoclonal antibody for infants

How I helped Pfizer think through the ethics of Viagra

Surprise medical billing ban raises prices elsewhere

How to ethically and practically extend health care to all

Elevance, SCAN deals highlight health insurer acquisition scrutiny

As AI regulations shape up, health tech startups beg for clarity

knowledge

explore

focus

explore